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Cysteine residues 86 and 91 of the b subunit of the
human interleukin (hIL)-3 receptor (hbc) participate in
disulfide-linked receptor subunit heterodimerization.
This linkage is essential for receptor tyrosine phospho-
rylation, since the Cys-86 3 Ala (Mc4) and Cys-91 3 Ala
(Mc5) mutations abolished both events. Here, we used
these mutants to examine whether disulfide-linked re-
ceptor dimerization affects the biological and biochem-
ical activities of the IL-3 receptor. Murine T cells ex-
pressing hIL-3Ra and Mc4 or Mc5 did not proliferate in
hIL-3, whereas cells expressing wild-type hbc exhibited
rapid proliferation. However, a small subpopulation of
cells expressing each mutant could be selected for
growth in IL-3, and these proliferated similarly to cells
expressing wild-type hbc, despite failing to undergo IL-
3-stimulated hbc tyrosine phosphorylation. The Mc4 and
Mc5 mutations substantially reduced, but did not abro-
gate, IL-3-mediated anti-apoptotic activity in the uns-
elected populations. Moreover, the mutations abolished
IL-3-induced JAK2, STAT, and AKT activation in the
unselected cells, whereas activation of these molecules
in IL-3-selected cells was normal. In contrast, Mc4 and
Mc5 showed a limited effect on activation of Erk1 and -2
in unselected cells. These data suggest that whereas
disulfide-mediated cross-linking and hbc tyrosine phos-
phorylation are normally important for receptor activa-
tion, alternative mechanisms can bypass these
requirements.
The receptors for human granulocyte-macrophage colony-
stimulating factor (GM-CSF),1 IL-3 and IL-5, are members of
the hematopoietin receptor superfamily, often termed the cy-
tokine receptor family. The high affinity GM-CSFzIL-3zIL-5
receptor complexes are composed of specific a chains that bind
GM-CSFzIL-3zIL-5 with low affinity (1–3) and a common b
chain (bc) that converts the binding to high affinity by forming
a heterodimer with the a subunit (4). The oligomerization of a
and b subunits mediated by ligand binding is thought to ini-
tiate signal transduction.
It is generally accepted that whereas the cytoplasmic do-
mains of both a and b subunits are required for receptor acti-
vation, in some cases dimerization of the cytoplasmic domain of
the b subunit alone is sufficient. This was demonstrated by a
study in which a chimeric receptor consisting of the extracel-
lular domain of the erythropoietin receptor and the intracellu-
lar domain of bc or bIL-3 was constructed. Erythropoietin in-
duced proliferation signals in Ba/F3 cells through the chimeric
receptors, indicating that the homodimerization of the b sub-
unit is sufficient for receptor activation (5). Likewise, a mutant
GM-CSF receptor a chain (GM-CSFRa), in which the cytoplas-
mic domain was replaced with that of the bc, formed a high
affinity receptor with the normal bc and transduced prolifera-
tive signals, again indicating the importance of the dimeriza-
tion of the b cytoplasmic domain (6). In contrast, the bc mutant
in which the cytoplasmic domain was substituted with that of
GM-CSFRa forms a high affinity GM-CSFR with the GM-
CSFRa but was unable to induce a proliferation signal, indi-
cating that the dimerization of the GM-CSFRa cytoplasmic
domain was not sufficient for signaling (6).
Despite the lack of an intrinsic tyrosine kinase in the recep-
tors, GM-CSF, IL-3, and IL-5 induce rapid tyrosine phospho-
rylation of various cellular proteins, including the b subunits
themselves. It is now known that cytoplasmic JAK family ty-
rosine kinases associate with the b subunit via conserved mem-
brane proximal regions known as “box-1” and “box-2” (7, 8). The
activated JAK kinases phosphorylate tyrosine residues of
many signaling proteins, among which are the latent cytoplas-
mic transcription factors known as signal transducer and acti-
vator of transcription (STAT). The activation of JAKs and/or
STATs is important for many if not all activities of cytokine
receptors (7, 9, 10).
The Ras-Raf-MAP kinase pathway is another major signal-
ing pathway activated in response to GM-CSF and IL-3 (11–
13). It has been demonstrated that a membrane-distal region of
bc is required for activation of the Ras-Raf-MAP kinase path-
way (11). Circumstantial evidence implies that JAK2 is also
required for activation of this pathway by IL-3 and GM-CSF.
Deletion of the box-1 region in bc (which is believed to be the
site of JAK2 association with bc) or expression of a dominant
negative form of JAK2 prevented phosphorylation of molecules
involved in Ras activation (Shc and SHP2) (7). Moreover, these
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same manipulations also blocked IL-3/GM-CSF-induced acti-
vation of the c-fos promoter (7, 14), which is also blocked by
dominant negative Ras (14). This pathway may also be impor-
tant for cell survival (15–17) (see also “Discussion”).
Signaling pathways that promote cell survival also include
the phosphatidylinositide-39-OH kinase (PI3K)-AKT pathway.
The AKT kinase is a general mediator of cytokine-induced
survival and has been shown to suppress the apoptotic death of
a number of cell types induced by a variety of stimuli, including
growth factor withdrawal, cell cycle discordance, loss of cell
adhesion, and DNA damage (18–21). Thus, a signaling path-
way has been defined in which cytokine receptor activation
leads to the sequential activation of PI3K and AKT, which then
promotes cell survival and blocks apoptosis.
Our previous study (22) showed that Cys-86 and Cys-91 but
not other Cys residues of human bc (hbc) participated in dis-
ulfide-linked receptor subunit heterodimerization. We also
showed that this linkage is essential for receptor phosphoryl-
ation because alanine substitutions of residues 86 (termed
Mc4) and 91 (Mc5), but not 100 (Mc7), abolished not only
IL-3-induced disulfide-linked IL-3 receptor subunit dimeriza-
tion but also tyrosine phosphorylation of hbc, without affecting
IL-3 binding. To investigate whether or not disulfide-mediated
cross-linking of IL-3 receptor subunits and phosphorylation of
hbc are essential for receptor signaling, we have now examined
the effects of these cysteine mutations on biological and bio-
chemical activities of the IL-3 receptor when expressed in the
murine T cell line CTL-EN. We have found that hbc mutants
Mc4 and Mc5 barely induce cell proliferation compared with
wild-type (WT) or Mc7. Interestingly, a subpopulation of cells
expressing each of the former mutants could be selected for
growth in IL-3, which, despite the absence of detectable hbc
tyrosine phosphorylation, proliferated at similar rates to cells
expressing WT hbc. Our data also show that Mc4 and Mc5 (but
not Mc7) impaired IL-3-facilitated protection against apoptosis
and failed to induce IL-3-stimulated JAK2, STAT, and AKT
activation in unselected cells. However, Mc4 and Mc5 had a
less severe effect on IL-3-induced Erk1/2 MAP kinase activa-
tion in the unselected cells. In contrast, in the IL-3-selected
cells, the cysteine mutations had no effects on IL-3-induced
activation of any of the signaling molecules that we examined.
EXPERIMENTAL PROCEDURES
Cell Culture—The ecotropic c2 retrovirus packaging cells were main-
tained in Dulbecco’s modified Eagle’s medium (DMEM) supplemented
with 10% heat-inactivated fetal calf serum (FCS), 2 mM L-glutamine,
and antibiotics. The IL-2-dependent mouse T cell line, CTL-EN (a
derivative of CTLL-2, described in Ref. 23), was maintained in CTLL
medium (DMEM supplemented with 10% FCS, 2 mM L-glutamine,
antibiotics, 50 mM b-mercaptoethanol, 5% conditioned medium from
MLA cells, and 100 units/ml bacterially synthesized mouse IL-2.
Construction of Expression Plasmids—Cysteine mutants Mc4, Mc5,
Mc7, or WT hbc cDNAs (22) were inserted between the BamHI and
HpaI restriction sites of the pRufHygro retroviral vector. The pRufHy-
gro retroviral vector was constructed by replacing the MC1Neo cassette
of pRufNeo (24) with a phosphoglycerate kinase/hygromycin resistance
cassette from pPGKHygro (25).
Transfection and Infection Procedures—The ecotropic packaging cell
line c2 was transfected by a standard calcium phosphate transfection
procedure as described (26) with 10 mg of retroviral plasmid containing
WT or cysteine mutant hbc per 10-cm dish. After overnight incubation
the cells were shocked with 2.5 ml of 15% glycerol in DMEM for 4 min
followed by a further 24 h incubation and then selected in hygromycin
(Roche Molecular Biochemicals) at 200 mg/ml. The selected cells were
sorted for expression of hbc, and collected in DMEM. These sorted c2
cells expressing WT or the cysteine mutant hbc were then used to infect
CTL-EN cells previously infected with a pRUFNeo retrovirus vector
(24) encoding the a chain of human IL-3 receptor (hIL-3Ra), using
procedures described previously (26). The infected CTL-EN cells were
selected in hygromycin at 600 mg/ml, and expression of WT or cysteine
mutant hbc on the surface of the hygromycin-resistant cells was exam-
ined by flow cytometry.
Cell Sorting and Analysis of Receptor Subunit Expression by Flow
Cytometry—Cells expressing WT or cysteine mutant hbc were collected
by cell sorting on a FACStarPLUS flow cytometer (Coulter, Hialeah, FL).
Briefly, cells were washed and resuspended in cold DMEM supple-
mented with 5% FCS. Cells were incubated with the anti-hbc mono-
clonal antibody 8B8 (27) for 20 min on ice, washed, and subsequently
incubated with fluorescein isothiocyanate-conjugated anti-mouse IgG
(Silenus, Hawthorn, Victoria, Australia) for 20 min on ice. After wash-
ing and resuspension in medium, the cells were sorted, and the positive
cells collected in CTLL medium.
Radiolabeling of Human IL-3 and Binding Assays—The procedures
used for radiolabeling of human IL-3 with 125I and performing satura-
tion-binding assays have been described previously (28, 29).
Cell Proliferation Assays—Infected CTL-EN cells expressing hIL-
3Ra and WT or cysteine mutant hbc were washed three times with
PBS, and triplicate samples of 5 3 103 cells were cultured in a 96-well
microtiter plate with or without IL-3 for 72 h. Cell proliferation was
measured by the CellTiter 96 Non-Radioactive Cell Proliferation Assay
(Promega, Madison, WI). The data were normalized with respect to
proliferation of the same cells cultured in 100 units/ml of IL-2.
Apoptosis Assays—Apoptotic cells were detected using the Annexin-
V-Fluos Staining kit (Roche Molecular Biochemicals) as per manufac-
turer’s instructions. Briefly, cells (5 3 105) were washed with PBS and
centrifuged at 2,000 3 g for 5 min. The cell pellets were resuspended in
100 ml of labeling solution (1:50 diluted Annexin-V-Fluos labeling rea-
gent in 10 mM HEPES buffer (pH 7.4) and 1 mg/ml of propidium iodide)
and then added to 0.4 ml of incubation buffer (10 mg of HEPES (pH 7.4),
140 mM NaCl, 5 mM CaCl2). The cells were analyzed on a flow cytometer
using a 488-nm excitation and a 515-nm band pass filter.
Immunoprecipitation—CTL-EN cells coexpressing hIL-3Ra and WT
or cysteine mutant hbc (4 3 107) were cultured overnight in the absence
of cytokines. Cells were washed with cold PBS followed by stimulation
at 37 °C for 5–15 min as indicated with varying concentrations of IL-3
(0–10 ng/ml) and then lysed on ice in lysis buffer (50 mM HEPES (pH
7.5), 150 mM NaCl, 10% glycerol, 1% Nonidet P-40, 0.1% SDS, 0.1%
sodium deoxycholate 2 mM sodium orthovanadate, 1 mM phenylmeth-
ylsulfonyl fluoride, 1 mM EDTA, 1 mM EGTA, 2 mg/ml iodoacetamide,
50 mM sodium fluoride, 10 mM sodium pyrophosphate, 0.2 mg/ml tryp-
sin inhibitor (Roche Molecular Biochemicals) and CompleteTM protease
inhibitor (Roche Molecular Biochemicals)) for 15 min. Insoluble mate-
rials were removed by centrifugation, and cell lysates were incubated
with rabbit anti-JAK2 antibody2 or anti-hbc monoclonal antibody 8E4
(30) for 2 h at 4 °C. Immune complexes were precipitated with 75 ml of
protein A-Sepharose (Amersham Pharmacia Biotech) for 90 min at 4 °C,
washed twice with lysis buffer, and boiled in 13 reducing SDS loading
buffer.
2 T. J. Blake and T. J. Gonda, unpublished data.
FIG. 1. Surface expression of WT or mutant (as indicated) hbc
in sorted CTL-EN/IL-3Ra cells as measured by flow cytometry
and indirect immunofluorescence. Dashed lines represent cells
stained with an irrelevant control antibody, and solid lines indicate
staining with an anti-hbc antibody 8B8.
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Western Blotting—Immunoprecipitates, or cell lysates prepared as
described above, were separated by SDS-polyacrylamide gel electro-
phoresis and electrophoretically transferred to ProtranR nitrocellulose
transfer membranes (Schleicher & Schuell). Membranes were incu-
bated with a blocking solution (3% bovine serum albumin in TBS-T (50
mM Tris-HCl (pH 7.4), 135 mM NaCl and 0.1% Tween 20)) at room
temperature for 1 h and then incubated overnight with antibody in the
same solution at 4 °C. The antibodies used were anti-JAK2 (as above);
anti-phosphotyrosine (4G10; Upstate Biotechnology, Inc., Lake Placid,
NY); anti-hbc (1C1; Ref. 28); anti-Erk1/2 (Zymed Laboratories Inc., San
Francisco, CA); anti-phospho-Erk1/2 (Promega, Madison, WI); and anti-
phospho-AKT and anti-AKT (Santa Cruz Biotechnology, Santa Cruz,
CA). The membranes were then washed three times in TBS-T solution
and incubated with anti-mouse or anti-rabbit secondary antibodies (as
appropriate) coupled with horseradish peroxidase (Pierce). Membranes
were washed in TBS-T three times and subjected to enhanced chemi-
luminescence detection as per the manufacturer’s instructions (Pierce).
Before reprobing, membranes were stripped in 50 mM Tris (pH 7.4), 2%
SDS, 100 mM b-mercaptoethanol at 55 °C for 10 mim, washed three
times in TBS-T, and blocked in TBS-T containing 3% bovine serum
albumin.
Electrophoretic Mobility Shift Analysis (EMSA) of STATs—Nuclear
extracts from CTL-EN cells expressing hIL-3Ra and WT or cysteine
mutant hbc were prepared as described by Jenkins et al. (31). These
were mixed with radiolabeled double-stranded oligonucleotides corre-
sponding to the prolactin-responsive element in the bovine b-casein
promoter, and EMSA was performed essentially as described by Barry
et al. (32).
RESULTS
Expression of WT or Cysteine Mutant hbc in Murine CTL-EN
Cells—To introduce WT or cysteine mutant hbc into CTL-EN
cells expressing hIL-3Ra, the cells were infected using c2 cells
producing the corresponding RUFHygro retroviruses. The in-
fected CTL-EN cells were selected in hygromycin in IL-2-con-
taining medium, and cell surface expression of hbc was as-
sessed by FACS analysis. Fig. 1 shows that WT and cysteine
mutant bc were expressed at comparable levels. Previous stud-
ies demonstrated that the cysteine mutations had no effect on
the ligand binding in HEK293T cells (22). To confirm this
finding in CTL-EN cells, we performed binding assays with
125I-IL-3. The results of Fig. 2 show that all receptors, either
WT or the cysteine mutants, had similar high affinity binding
and were present in similar numbers, in agreement with pre-
vious results in HEK293T cells (22) and the FACS analyses of
Fig. 1.
Effects of the hbc Cysteine Mutations on IL-3-induced Prolif-
eration—The growth of CTL-EN cells expressing WT hbc or the
cysteine mutants cultured in hIL-3 (10 ng/ml) was monitored
over a 3-day period. The results of Fig. 3A show that cells
expressing Mc4 and Mc5 mutants did not exhibit detectable
growth, whereas cells expressing the Mc7 mutant grew simi-
larly to those expressing WT hbc. Interestingly, it was found
that although most cells expressing Mc4 and Mc5 mutants
could not grow or survive in IL-3, a small subset (we estimate
#1%) of these cells grew out over a period of several weeks from
IL-3-containing cultures. To distinguish these subsets, which
were maintained in medium containing hIL-3, we will term
these cells “IL-3-selected cells,” whereas the bulk population of
(mutant) hbc-expressing cells, maintained in IL-2, will hereaf-
ter be termed “unselected cells.” It was found that the IL-3-
selected cells proliferated at similar rates to the cells express-
ing WT hbc (Fig. 3B) and did not grow or survive in medium
lacking cytokines (data not shown). Moreover, polymerase
chain reaction amplification and sequencing of hbc from
genomic DNA of the IL-3-selected cells confirmed the presence
of the cysteine mutations, i.e. these cells were not genetic
revertants.
Cysteine Mutations Mc4 and Mc5 Markedly Impair hIL-3-
facilitated Protection against Apoptosis—To examine whether
the Mc4 and Mc5 mutations have an effect on cell survival,
unselected CTL-EN cells expressing WT or cysteine mutant
hbc were cultured in different concentrations of IL-3 for 48 h,
following which the proportions of apoptotic cells were deter-
mined by annexin-V staining and FACS analysis. The results
in Fig. 4A show that IL-3 at either low or high concentrations
effectively protected the cells expressing WT or Mc7 from ap-
optosis in a dose-dependent manner. The cysteine mutations
Mc4 and Mc5 significantly impaired, but importantly, did not
completely abrogate the ability of IL-3 to protect the cells
against apoptosis. This result was confirmed in the time course
experiment shown in Fig. 4B. The impairment by Mc4 and Mc5
of hIL-3-facilitated protection against apoptosis was evident at
48 h and was even more marked by 72 h.
The Cysteine Mutations Mc4 and Mc5 Prevent Tyrosine Phos-
FIG. 2. Scatchard transformation of saturation binding stud-
ies performed on CTL-EN cells coexpressing hIL-3Ra and WT or
cysteine mutant hbc as indicated. Binding assays were performed
with 125I-labeled IL-3 over a concentration range of 10 pM to 10 nM. The
data were analyzed using the LIGAND program, and the lines indicate
the high affinity binding component for WT or Cys mutant hbc as
indicated.
FIG. 3. Proliferation of unselected
CTL-EN cells (A) or IL-3-selected
CTL-EN cells (B) coexpressing hIL-
3Ra and WT or cysteine mutant hbc
as indicated. 5 3 103 cells were plated in
triplicate, and cell proliferation was
measured at each time point as described
under “Experimental Procedures.” The
absorbance was normalized to that of the
same cells cultured in IL-2 for 3 days. The
mean and standard error of each tripli-
cate is shown.
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phorylation of hbc in CTL-EN Cells—We previously showed
that cysteine mutations Mc4 and Mc5 abrogated disulfide-
linked IL-3 receptor dimerization and abolished tyrosine phos-
phorylation of hbc in response to IL-3 when expressed in
HEK293T cells. To test whether this was also the case in the
IL-3-selected CTL-EN cells, we performed Western blot analy-
sis to detect tyrosine phosphorylation of hbc. The results of Fig.
5 show that the cysteine mutations Mc4 and Mc5 abolished
IL-3-induced receptor tyrosine phosphorylation, which was,
however, readily detected in cells expressing WT or Mc7.
Effects of Cysteine Mutations Mc4 and Mc5 on JAK2 and
STAT Activation—The activity of JAK2 is believed to be nec-
essary for all the biological functions of IL-3 and GM-CSF (7).
We therefore examined the effects of the Mc4 and Mc5 muta-
tions on JAK2 and STAT activation. In the case of unselected
cells, it was found that phosphorylation of JAK2 was observed
in cells expressing WT or Mc7 after stimulating the cells with
10 ng/ml hIL-3 but not in cells expressing the Mc4 or Mc5
mutants (Fig. 6A). Although no JAK2 activation was detected
when the cells expressing WT or Mc7 were stimulated with a
low concentration of hIL-3 (1 ng/ml), we found that IL-3 at a
concentration of 1 ng/ml was able to support proliferation of
cells expressing WT or Mc7 (data not shown; see also below).
One class of effectors of JAK2 are the STAT transcription
factors, which are phosphorylated and activated by JAK2. We
therefore examined nuclear extracts from unselected cells ex-
pressing WT or mutant hbc for the presence of STAT DNA
binding activity by performing EMSAs. After stimulation of the
cells with 10 ng/ml IL-3, extracts from cells expressing WT or
Mc7 contained a protein complex that specifically bound to a
b-casein oligonucleotide probe containing a DNA-binding site
for STATs 1, 3, and 5 (Fig. 6B). However, no STAT activation
was detected in cells expressing the Mc4 or Mc5 mutants (Fig.
6B) after stimulation by IL-3. Weak STAT activation was also
detected in cells expressing WT or Mc7 stimulated with 1 ng/ml
IL-3. The most likely explanation for this, considering that no
JAK2 activation was detected with this concentration of IL-3, is
simply that EMSA detection of STAT activity is more sensitive
than detection of JAK2 tyrosine phosphorylation.
Because, as mentioned above, a subpopulation of cells ex-
pressing the cysteine mutants Mc4 or Mc5 could be selected for
growth in IL-3, we investigated whether or not JAK2 and
STATs were activated in IL-3-selected cells expressing these
mutants. Fig. 6, C and D, shows that JAK2 and STAT activa-
tion was detected following stimulation with IL-3 at 10 ng/ml
not only in cells expressing WT or Mc7 but, in contrast to the
unselected cells, also in cells expressing Mc4 or Mc5. As for Mc7
and WT, weak activation of STAT but not JAK2 was also
detected when a low concentration of IL-3 was used.
Effects of Cysteine Mutations Mc4 and Mc5 on Ras-Raf-MAP
Kinase Pathway—One of the major signaling pathways acti-
vated in response to cytokines is the Ras-Raf-MAP kinase
pathway (11, 12). To examine whether the cysteine mutations
have an effect on hbc-mediated activation of Erk1/2 MAP ki-
nases, Western blot analyses of cell lysates from both uns-
elected and IL-3-selected cells with an antibody specific for
activated, i.e. phosphorylated, Erk1/2 MAP kinases were con-
ducted. Fig. 7A shows that phosphorylation of Erk1/2 MAP
kinases was detected in unselected cells expressing WT or Mc7
mutant hbc when the cells were stimulated with 1 or 10 ng/ml
hIL-3. Moreover, Erk1/2 phosphorylation was also clearly de-
tected when cells expressing Mc4 or Mc5 were stimulated with
10 ng/ml hIL-3, although little or no phosphorylation above
background was detected with 1 ng/ml hIL-3. In the case of
IL-3-selected cells, activation of Erk1/2 MAP kinases was
readily detectable in cells expressing WT and all of the cysteine
mutant forms of hbc, regardless of whether the cells were
stimulated with a low or high concentration of hIL-3 (Fig. 7B).
Effects of Cysteine Mutations Mc4 and Mc5 on AKT Kinase—
The activation of the PI3K and its downstream effector AKT
has been shown to promote cell survival and suppress apoptosis
(18–20). We therefore examined the levels of activated AKT
kinase in both unselected and IL-3-selected CTL-EN cells ex-
pressing WT or mutant hbc. Western blot analysis of cell ly-
sates from unselected cells using an antibody specific for phos-
phorylated AKT showed that AKT was activated in cells
expressing WT or Mc7 but not in cells expressing Mc4 or Mc5
following stimulation with IL-3 at either 1 or 10 ng/ml (Fig.
8A). In contrast, when the IL-3-selected cells were similarly
treated and analyzed, activated AKT kinase was detected in
cells expressing either WT or any of the mutant forms of hbc
(Fig. 8B).
FIG. 4. Apoptosis of unselected
CTL-EN cells coexpressing hIL-3Ra
and WT or cysteine mutant hbc. A, the
cells were incubated with the indicated
concentrations of hIL-3 for 48 h and then
stained with annexin-V and analyzed by
flow cytometry to detect the percentage of
annexin-V-stained cells. B, the same cell
populations were incubated with 1 ng/ml
hIL-3 or without hIL-3 (control). At each
time point as indicated the cells were
stained with annexin-V and analyzed by
flow cytometry.
FIG. 5. The cysteine mutations Mc4 and Mc5 prevent IL-3-
induced tyrosine phosphorylation of hbc in IL-3-selected
CTL-EN cells coexpressing hIL-3Ra and WT or cysteine mutant
hbc. Upper panel, the cells were stimulated with 10 ng/ml hIL-3 for 5
min or left unstimulated, as indicated. After cell lysis, proteins were
immunoprecipitated with anti-hbc monoclonal antibody 8E4, and the
immunoprecipitates were separated by SDS-polyacrylamide gel electro-
phoresis and analyzed by Western blotting (WB) with anti-phosphoty-
rosine antibody 4G10. Lower panel, the filters were stripped and
reprobed with anti-bc monoclonal antibody, 1C1.
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DISCUSSION
We previously showed (28) the presence of IL-3-induced dis-
ulfide-linked and non-disulfide-linked heterodimers, suggest-
ing two levels of IL-3Ra and bc interaction, a noncovalent one
and one that is mediated by Cys-Cys bridging of the receptors.
Furthermore, substitution of alanine for cysteines 86 (Mc4) or
91 (Mc5) abolished disulfide-linked IL-3 receptor dimerization
and tyrosine phosphorylation of bc subunit but had no effect on
high affinity binding between ligand and receptor, nor on IL-
3-dependent coimmunoprecipitation of a and b subunits (22).
This suggests that disulfide-linked dimerization is essential for
receptor phosphorylation. The present studies were designed to
determine whether blocking disulfide-linked dimerization has
effects on biological and biochemical functions of the IL-3 re-
ceptor. To this end, we utilized populations of (normally) IL-2-
dependent CTL-EN cells expressing WT or cysteine mutant
forms of hbc along with hIL-3Ra.
We have shown here that the cysteine mutations Mc4 and
Mc5 almost completely inhibited IL-3-induced proliferation of
CTL-EN cells. Another cysteine mutant, Mc7, which showed
normal disulfide-linked dimerization and tyrosine phosphoryl-
ation in transfected HEK 293T cells (22), behaved like WT hbc
and had no effect on cell proliferation. Interestingly, despite the
fact that most of the CTL-EN cells expressing Mc4 or Mc5 could
not proliferate in IL-3, a small fraction survived and continued
to proliferate in IL-3 at similar rates to cells expressing WT hbc
and Mc7. Nevertheless, and unlike WT- and Mc7-expressing
cells, IL-3-selected cells expressing Mc4 or Mc5 did not undergo
IL-3-induced hbc phosphorylation.
Analyses of several key intracellular signaling molecules
showed that most of these, JAK2, STATs, and Akt, were not
activated in response to IL-3 in unselected cells expressing Mc4
or Mc5 but were activated in the corresponding IL-3-selected
populations. Thus triggering of these pathways correlated well
with the ability of the cells to proliferate in IL-3; this finding
was not totally unexpected since considerable evidence indi-
cates that JAK2 activation is an essential and primary effector
of receptor function (7, 33). More unexpectedly, the Erk1/2
MAP kinases were activated by IL-3 in both populations, al-
though it appeared that higher concentrations may be neces-
sary in the case of the unselected Mc4- or Mc5-expressing cells.
The fact that IL-3-selected cells expressing the Mc4 and Mc5
mutants could proliferate normally in response to IL-3 without
detectable hbc phosphorylation provides independent confir-
FIG. 7. Effects of the cysteine muta-
tions on IL-3-induced Erk1/2 MAP ki-
nase phosphorylation. A, unselected
CTL-EN cells expressing WT or cysteine
mutant hbc plus hIL-3Ra were stimu-
lated with the indicated concentrations of
hIL-3 for 15 min. Cell lysates were immu-
noblotted with anti-phospho-Erk1/2 (up-
per panel) or anti-Erk1/2 (lower panel). B,
IL-3-selected cells were analyzed exactly
as in A. WB, Western blotting.
FIG. 8. Effects of the cysteine muta-
tions on IL-3-induced AKT kinase ac-
tivation. A, unselected CTL-EN cells ex-
pressing WT or cysteine mutant hbc plus
hIL-3Ra as indicated were stimulated for
15 min with the IL-3 at the indicated con-
centrations. The cell lysates were immu-
noblotted with anti-phospho-AKT (upper
panel) or anti-AKT antibodies (lower pan-
el). B, IL-3-selected cells expressing WT
or mutant hbc were analyzed as in A. WB,
Western blotting.
FIG. 6. Effects of cysteine mutations
on IL-3-induced activation of JAK2
and STATs in unselected (A and B) or
IL-3-selected CTL-EN cells (C and D).
A, the unselected CTL-EN cells express-
ing WT or cysteine mutant hbc plus hIL-
3Ra were incubated with the indicated
concentration of hIL-3 for 5 min. Lysates
from the cells were subject to immunopre-
cipitation with anti-JAK2 antibodies fol-
lowed by Western blotting (WB) with anti-
phosphotyrosine antibodies 4G10 (upper
panel) or anti-JAK2 antibodies (lower
panel). B, the unselected cells expressing
WT or cysteine mutant hbc plus IL-3Ra
were incubated with different concentra-
tions of IL-3 for 15 min as indicated. Nu-
clear extracts prepared from the cells
were subjected to EMSA using a b-casein
promoter oligonucleotide probe. C and D,
IL-3-selected cells were analyzed as for A
and B, respectively.
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mation of other studies that dissociate these two properties.
Okuda et al. (34), Itoh et al. (35), and Guthridge et al. (36) all
reported that a mutant of hbc in which all eight cytoplasmic
tyrosines were replaced by phenylalanine could still transduce
proliferative signals, albeit less efficiently than WT hbc. In
addition, our own studies with constitutively activated point
mutants of hbc (31) showed that one class of such mutants
failed to show detectable tyrosine phosphorylation but still
elicited rapid proliferation and activation of JAK2, STATs, and
Erk1/2. These results also highlight the possibility that serine/
threonine phosphorylation of hbc may contribute to some of the
activities of the IL-3 receptor.
We previously proposed a model for the activated, disulfide-
linked GM-CSF, IL-3, and IL-5 receptor complexes in which the
activated receptor consists of two cytokine molecules, two a
chains and two bc chains, i.e. of two disulfide-linked a-b dimers
(22, 37). Formation of this hexameric receptor complex would
result in juxtaposition of two bc molecules with their associated
JAK kinases, facilitating JAK2 activation and inducing recep-
tor phosphorylation. This model would explain why the Mc4
and Mc5 mutants, which cannot form disulfide-linked a-b
dimers, are unable to induce JAK2 activation and proliferation
in the unselected cells. However, the ability of the IL-3-selected
cells expressing Mc4 or Mc5 to proliferate normally and acti-
vate JAK2 strongly suggests that there can exist other forms of
the activated receptor, in addition to the disulfide-linked com-
plex. As we have suggested for certain constitutive hbc mu-
tants (23), it may be that a-b dimers can be active in some
circumstances. Alternatively, the Mc4 and Mc5 mutants may
be able to form a spatially “incorrect” non-covalently linked
higher order complex in which JAK2 activation does not result
in hbc phosphorylation.
Analyses of intracellular signaling by the cysteine mutant
receptors in unselected and IL-3-selected CTL-EN cells
strongly supports the essential role of JAK2 activation in the
induction of proliferation and an important role in maintaining
cell survival. Our data are also consistent with an important
role for Akt in IL-3-mediated maintenance of cell viability (19,
21), since the absence of IL-3-induced activation of Akt in
unselected Mc4- or Mc5-expressing cells correlated with mark-
edly increased apoptotic death. More surprising was our find-
ing that IL-3 induced activation of Erk1/2 even in the uns-
elected cells, i.e. in the absence of detectable JAK2 activation.
(We believe that assaying JAK2 activation by its tyrosine phos-
phorylation is relatively insensitive; however, the EMSA detec-
tion of STAT activation appears to be a much more sensitive,
albeit surrogate, assay. This, too, was negative in the uns-
elected Mc4- or Mc5-expressing cells.) While it is generally
thought that JAK2 activation is essential for activation of the
Ras/Raf/Erk pathway, the evidence for this, in the case of the
GM-CSF/IL-3 receptors, is mostly circumstantial (see “Intro-
duction”), although more direct evidence has been published for
other cytokine receptors (38, 39). However, a mutant of the
thrombopoietin receptor, Mpl, has been described which acti-
vates Erk1/2 in the absence of detectable JAK or STAT activa-
tion, and dominant negative JAK2 only partially inhibited Erk
activation by gp130 (40), supporting the notion that cytokine
receptors may be able to activate Erk kinases by a JAK-inde-
pendent mechanism (41). The apparently lower sensitivity of
Erk1/2 activation to IL-3 in the unselected cells needs further
study but is consistent with the utilization of an alternate, less
efficient pathway than in IL-3-selected or WT-expressing cells.
The activation of Erk1/2 in unselected Mc4- and Mc5-ex-
pressing CTL-EN cells is also interesting in the light of the
partial resistance of these cells, in the presence of IL-3, to
apoptosis. There are apparently contradictory reports on the
importance of Erk1/2 activation in the anti-apoptotic activity of
the GMR/IL3R/IL5R system and in hemopoietic cells in general
(discussed in Ref. 42), but several studies have shown that
activation of these molecules can at least contribute to anti-
apoptotic function (15, 17). Thus, the ability of Mc4 and Mc5 to
promote some survival of the unselected cells may be due, at
least in part, to activation of Erk1/2; future studies with spe-
cific inhibitors could clarify this issue, but our results never-
theless suggest that the anti-apoptotic activity of IL-3 probably
involves multiple pathways (42, 43).
An intriguing question raised by our present studies relates
to the emergence of the IL-3-selected subpopulations of
CTL-EN cells expressing Mc4 and Mc5. That is, in what way(s)
do the selected cells differ from the bulk of the population? The
trivial explanations of genetic reversion or spontaneous factor
independence have been ruled out. It is formally possible that
culture in IL-3 has selected for a second-site mutation in hbc
that somehow compensates for the Mc4 and Mc5 mutations
(without restoring hbc tyrosine phosphorylation). However the
fact that with both Mc4 and Mc5, IL-3-responsive cells grew out
in each of two independent experiments suggests it is far more
likely that there is an intrinsic difference in the selected cells
themselves. One possible explanation is that (i) the selected
cells represent those that express the highest levels of a par-
ticular accessory signaling molecule and (ii) high levels of this
molecule can enhance the efficiency of signaling by an a-b
dimer or non-covalent higher order complex (see above). Al-
though there are no obvious candidates for such a molecule, we
note that SH2-Bb has recently been shown to interact with and
enhance activation of JAK2 (44); high levels of a molecule such
as this could readily account for the properties of the IL-3-
selected cells.
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